Amy Hamilton
Medical · Shenandoah, TXNPI 1205879210
Payments from drug & device makers
Across 166 payments — averaging $19.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$662
- Boehringer Ingelheim$485
- Lilly USA, LLC$408
- GSK$339
- Pfizer$197
- Amgen$176
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,306100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 38 | $662 |
| Boehringer Ingelheim | 22 | $485 |
| Lilly USA, LLC | 23 | $408 |
| GSK | 13 | $339 |
| Pfizer | 10 | $197 |
| Amgen | 3 | $176 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $163 |
| Exact Sciences | 7 | $146 |
| Gilead | 4 | $71 |
| Merck | 4 | $68 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $64 |
| Esperion Therapeutics, Inc. | 3 | $57 |
| AstraZeneca | 3 | $50 |
| Azurity Pharmaceuticals, Inc. | 2 | $47 |
| Abbott | 2 | $39 |
| Amarin Pharma, Inc. | 2 | $38 |
| Organon | 1 | $32 |
| Eisai Inc. | 2 | $31 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| IBSA Pharma Inc. | 2 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $29 |
| Currax Pharmaceuticals LLC | 2 | $28 |
| Teva Pharmaceuticals USA, Inc. | 1 | $27 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| Seqirus USA Inc | 1 | $22 |
| Alk-abello, Inc | 1 | $17 |
| Dexcom, Inc. | 1 | $14 |
| Genentech USA, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,306 in reported general payments places this provider in the 75th percentile of 1,490 medical providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 32 | $33,812 |
| MounjaroTirzepatide | 15 | $24,799 |
| JardianceEmpagliflozin | 13 | $14,006 |
| Levothyroxine Sodium | 117 | $1,080 |
| Atorvastatin Calcium | 95 | $762 |
| Rosuvastatin Calcium | 53 | $636 |
| Gabapentin | 34 | $632 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 15 | $562 |
| Etodolac | 15 | $462 |
| Allopurinol | 18 | $390 |
| Meloxicam | 44 | $363 |
| Olmesartan Medoxomil | 12 | $356 |
| Fluticasone Propionate | 14 | $312 |
| Omeprazole | 18 | $307 |
| Amlodipine Besylate | 51 | $304 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $662 | $33,81232 claims |
| Lilly USA, LLCMounjaro | $408 | $24,79915 claims |
| Boehringer IngelheimJardiance | $485 | $14,00613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,490 medical providers in Texas.
Other medical in Shenandoah
- Jose de la CerdaSan Antonio$1.1M
- Mark DavisFort Worth$1M
- Joey Dixon-JulianBoerne$458K
- Terry FaleyeKingwood$243K
- Kimberly PoarchDallas$166K
- Erin DuhaimeDallas$150K
- Courtney AldridgeSan Antonio$129K
- Shakira CabreraSan Antonio$116K
- Danny DeckardDallas$101K
- Janine ShinnDallas$84K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.